SCHEMBL25348552

SCHEMBL25348552

COc1c(F)cc(F)c(OC)c1I

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.33
ACHE P22303 1/20 0.33
PDGFRB P09619 1/20 0.33
PDGFRA P16234 1/20 0.33
TUBB1 Q9H4B7 4/20 0.33
DBH P09172 1/20 0.33
CYP3A4 P08684 1/20 0.32
MAPT P10636 1/20 0.32
CA9 Q16790 1/20 0.32
GRIN2D O15399 1/20 0.32
GRIN3B O60391 1/20 0.32
GRIN1 Q05586 1/20 0.32
GRIN2A Q12879 1/20 0.32
GRIN2B Q13224 1/20 0.32
GRIN2C Q14957 1/20 0.32
GRIN3A Q8TCU5 1/20 0.32
TPMT P51580 1/20 0.31
HTR2A P28223 1/20 0.31
HTR2C P28335 1/20 0.31
HTR2B P41595 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25222005 0.83 CYP3A4 (0.33) TDP1ACHEPDGFRBPDGFRATUBB1
SCHEMBL3841907 0.80 ILK (0.33) CYP3A4MAPT
SCHEMBL31015975 0.80 ILK (0.33) CYP3A4MAPT
SCHEMBL3358050 0.79 PDGFRB (0.37) TDP1ACHEPDGFRBPDGFRATUBB1
SCHEMBL22883762 0.78 TDP1 (0.36) TDP1ACHEPDGFRBPDGFRATUBB1
SCHEMBL15510333 0.77 CA2 (0.36) ACHECA2CA4
SCHEMBL5656538 0.75 MCL1 (0.44) TDP1TUBB1MAPTCA2ALDH1A1
SCHEMBL6739577 0.74 TUBB1 (0.35) TDP1ACHEPDGFRBPDGFRATUBB1
SCHEMBL23898583 0.73 HSD17B10 (0.32)
SCHEMBL17210735 0.73 TTR (0.39) TDP1ACHEPDGFRBPDGFRATUBB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240043420-A1 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES ENLIVEN INC. 2024-02-08 US disclosed
EP-4225741-A1 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES Enliven Therapeutics, Inc. (US) 2023-08-16 EP disclosed
CN-116438182-A 7-azaindole compounds for inhibiting BCR-ABL tyrosine kinase 活力疗法公司 2023-07-14 CN disclosed
WO-2022076973-A1 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES ENLIVEN THERAPEUTICS, INC. (US) 2022-04-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240043420-A1 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES ABL1, ABL2, BCR TDP1 1977/4885ACHE 4660/4885PDGFRB 162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.